Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
Ramesh K. Ramanathan, Marwan Fakih, Sridhar Mani, Melvin Deutsch, Raymond P. Perez, Mark A. Ritter, Julie L. Eiseman, S. Percy Ivy, Donald L. Trump, Chandra P. Belani, Robert A. Parise, Douglas M. Potter, Merrill J. Egorin
Fingerprint
Dive into the research topics of 'Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers'. Together they form a unique fingerprint.